Blueprint Medicines Corporation develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which completed Phase I clinical trials that targets PDGFRA Exon 18 mutant GIST and KIT-driven GIST; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone617-374-7580
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$44.52 million
Profitability
Miscellaneous
Employees217
Next Earnings Date10/29/2019 (Estimated)
OptionableOptionable
Blueprint Medicines (NASDAQ:BPMC) Frequently Asked Questions
What is Blueprint Medicines' stock symbol?
Blueprint Medicines trades on the NASDAQ under the ticker symbol "BPMC."
How were Blueprint Medicines' earnings last quarter?
Blueprint Medicines Corp (NASDAQ:BPMC) posted its quarterly earnings results on Thursday, August, 1st. The biotechnology company reported ($2.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.92) by $0.12. The biotechnology company earned $5.11 million during the quarter, compared to the consensus estimate of $1.39 million. Blueprint Medicines had a negative net margin of 4,268.74% and a negative return on equity of 73.73%. The business's revenue for the quarter was down 87.7% on a year-over-year basis. During the same period last year, the firm earned ($0.62) EPS. View Blueprint Medicines' Earnings History.
When is Blueprint Medicines' next earnings date?
What price target have analysts set for BPMC?
10 analysts have issued twelve-month price targets for Blueprint Medicines' shares. Their forecasts range from $85.00 to $125.00. On average, they anticipate Blueprint Medicines' share price to reach $109.00 in the next year. This suggests a possible upside of 45.0% from the stock's current price. View Analyst Price Targets for Blueprint Medicines.
What is the consensus analysts' recommendation for Blueprint Medicines?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Blueprint Medicines in the last year. There are currently 1 hold rating and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Blueprint Medicines.
Has Blueprint Medicines been receiving favorable news coverage?
Press coverage about BPMC stock has trended negative recently, according to InfoTrie. The research firm rates the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Blueprint Medicines earned a news sentiment score of -2.0 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Blueprint Medicines.
Are investors shorting Blueprint Medicines?
Blueprint Medicines saw a increase in short interest in September. As of September 30th, there was short interest totalling 4,020,000 shares, an increase of 18.9% from the August 30th total of 3,380,000 shares. Based on an average daily trading volume, of 419,100 shares, the days-to-cover ratio is presently 9.6 days. Approximately 8.4% of the shares of the stock are sold short. View Blueprint Medicines' Current Options Chain.
Who are some of Blueprint Medicines' key competitors?
Some companies that are related to Blueprint Medicines include UCB (UCBJF), GRIFOLS S A/S (GRFS), Genmab A/S (GNMSF), BioMarin Pharmaceutical (BMRN), Array Biopharma (ARRY), Elanco Animal Health (ELAN), Mylan (MYL), Ono Pharmaceutical (OPHLF), Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals (IONS), GALAPAGOS NV/S (GLPG), Teva Pharmaceutical Industries (TEVA), Bausch Health Companies (BHC), SAGE Therapeutics (SAGE) and Perrigo (PRGO).
What other stocks do shareholders of Blueprint Medicines own?
Who are Blueprint Medicines' key executives?
Blueprint Medicines' management team includes the folowing people:
- Mr. Jeffrey W. Albers, CEO, Pres & Director (Age 48)
- Mr. Alexis A. Borisy, Co-Founder & Director (Age 47)
- Mr. Michael Landsittel, Chief Financial Officer (Age 47)
- Ms. Kathryn Haviland, Chief Operating Officer (Age 43)
- Dr. Christopher K. Murray, Sr. VP of Technical Operations (Age 56)
When did Blueprint Medicines IPO?
(BPMC) raised $115 million in an initial public offering on Thursday, April 30th 2015. The company issued 7,200,000 shares at $15.00-$17.00 per share. Goldman Sachs and Cowen and Company acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.
Who are Blueprint Medicines' major shareholders?
Blueprint Medicines' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Avitas Wealth Management LLC (0.06%), Zeke Capital Advisors LLC (0.01%), Nelson Van Denburg & Campbell Wealth Management Group LLC (0.01%), Zurcher Kantonalbank Zurich Cantonalbank (0.01%) and Whittier Trust Co. (0.00%). Company insiders that own Blueprint Medicines stock include Alexis Borisy, Anthony L Boral, Ariel Hurley, Charles A Rowland Jr, Daniel Lynch, George Demetri, Jeffrey W Albers, Kate Haviland, Lonnel Coats, Marion Dorsch and Nicholas Lydon. View Institutional Ownership Trends for Blueprint Medicines.
Which institutional investors are buying Blueprint Medicines stock?
BPMC stock was acquired by a variety of institutional investors in the last quarter, including Avitas Wealth Management LLC, Zeke Capital Advisors LLC, Nelson Van Denburg & Campbell Wealth Management Group LLC, Whittier Trust Co. and Zurcher Kantonalbank Zurich Cantonalbank . View Insider Buying and Selling for Blueprint Medicines.
How do I buy shares of Blueprint Medicines?
Shares of BPMC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Blueprint Medicines' stock price today?
One share of BPMC stock can currently be purchased for approximately $75.15.
How big of a company is Blueprint Medicines?
Blueprint Medicines has a market capitalization of $3.69 billion and generates $44.52 million in revenue each year. The biotechnology company earns $-236,640,000.00 in net income (profit) each year or ($5.39) on an earnings per share basis. Blueprint Medicines employs 217 workers across the globe.View Additional Information About Blueprint Medicines.
What is Blueprint Medicines' official website?
How can I contact Blueprint Medicines?
Blueprint Medicines' mailing address is 45 SIDNEY STREET, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-374-7580 or via email at [email protected]
MarketBeat Community Rating for Blueprint Medicines (NASDAQ BPMC)
MarketBeat's community ratings are surveys of what our community members think about Blueprint Medicines and other stocks. Vote "Outperform" if you believe BPMC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BPMC will underperform the S&P 500 over the long term. You may vote once every thirty days.
